Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M032 in Newly Diagnosed Diffuse Midline Glioma
NCT07076498Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of M032 in diffuse midline glioma (DMG) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and Adverse Events and Maximum Tolerated Dose. Started Apr 2026; status: recruiting.
02
Drugs
M032
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT07076498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076498.